Health
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis (RMS)Both studies showed positive trends in reducing disability progression with fenebrutinib compared to teriflunomideFenebrutinib could become a first-in-class BTK inhibitor and the first and only high-efficacy oral for both RMS and primary progressive multiple sclerosis (PPMS)The totality of R
About this update from Roche Holding Ltd
[{"type":"image","alt":"F. Hoffmann-La Roche Ltd","displaySize":"","headline":null,"caption":"F. Hoffmann-La Roche Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MSaNoVyiQkMLafN4Lv5PPQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Nw--/https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2","width":300,"height":198}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis (RMS)","length":208,"tagName":"p"}]},{"val":[{"type":"text","content":"Both studies showed positive trends in reducing disability progression with fenebrutinib compared to teriflunomide","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"Fenebrutinib could become a first-in-class BTK inhibitor and the first and only high-efficacy oral for both RMS and primary progressive multiple sclerosis (PPMS)","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"The totality of RMS and PPMS data for fenebrutinib will be submitted to regulatory authorities","length":94,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":577,"olType":false},{"type":"text","content":"Basel, 22 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the positive Phase III FENhance 1 and 2 studies, which met their primary endpoint. The studies showed that fenebrutinib, an investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, reduced the annualised relapse rate (ARR) by 51.1% (p<0.001) in FENhance 1 and 58.5% (p<0.0001) in FENhance 2 compared with teriflunomide in patients with relapsing multiple sclerosis (RMS) over 96 weeks. This equates to patients having approximately one relapse every 17 years, more than half the relapses seen with teriflunomide in the same period of time. The results were shared today as a late-breaking presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago.","length":784,"tagName":"p"},{"type":"text","content":"“These results underscore that fenebrutinib has potential as a high-e...